Development and Characterization of Methotrexate Bearing Emulsomes for Management of Skin Cancer
Abstract
The present study is aimed to manage skin cancer via topical route, because of conventional chemotherapy having lots of drawbacks like drugs introduced into the body through an injectable route thus drugs are distributed between normal cell and cancerous cell than its leading to unaccepted side effects and requires high dose of drug. In this paper, main focus onto overcome these drawbacks, emulsomes were developed loaded with methotrexate bio-active agent. A 32 factorial design approach was employed firstly for the formulation development of emulsomes for different concentration of lipid content which was phosphatidyl choline, cholesterol and solid core lipid. Developed methotrexate loaded emulsomes were characterized for particle size, polydispersity index, zeta potential and entrapment efficiency and results revealed 127.21 ± 1.11 nm, 0.216, -24.21 ± 1.09 mv, and 81.37 ± 0.8%, respectively. Thus optimized lipid content was further used for optimization of type and concentration of surfactants9 and sonication time. Hence 18 formulations of emulsomes were developed and characterized for particle size, polydispersity index, zeta potential and entrapment efficiency and result 126 ± 1.09 nm, 0.215, -24.81 ± 1.19 mv, and 85.17 ± 0.3%, respectively. These formulations were tested for their in-vitro drug release studies and release data show the value of t½ for formulations EM4F11, EM4F18 and EM4F8 was more than 12 h and they were retarded drug release up to 85% till 24 h to get better-sustained drug release profile. Then stability study was performed for formulation EM4F11 at 2 ± 2°C, 25 ± 2°C and 60% RH and 40 ± 2°C and 75% RH and data identified that the formulations stored at temperature 25 ± 2°C and 60% RH and it was less than 2% degradation at the end of six months. Hence developed emulsomes formulation might represent a promising system for improving the bioavailability of lipophilic drugs. Moreover, emulsomes produce sustained drug release, which is beneficial clinically. Thus the presented system adds additional benefits to the well-known opportunities to the conventional delivery system and is helpful in minimizing the side effects of anti-cancerous drugs and well suited for the management of skin ailment.
Keywords:
Emulsomes, Factorial design, Skin cancer, Topical deliveryDOI
https://doi.org/10.25004/IJPSDR.2022.140517References
Prausnitz MR, Elias PM, Franz TJ, Schmuth M,Tsai JC, Menon GK, Holleran WM, Feingold KR. Skin Barrier and Transdermal Drug Delivery. Medical Therapy, Section 19, chapter 124, 2012, pp. 2065-2074.
D’Orazio J, Jarrett S, Amaro-Ortiz A, Scott T. UV radiation and the skin. Int J Mol Sci. 2013; 14:12222-12248.
Simões MCF, Sousa JSS, Pais AA. Skin cancer and new treatment perspectives: a review. Cancer Letters. 2015; 1:8-42.
Ghissassi El F, Baan R, Straif K. WHO international Agency for research on cancer monograph working group. A review of human carcinogens-part D: radiation. Lancet Oncol. 2009; 10:751-752.
Rigon RB, Oyafuso MH, Fujimura AT, Goncalez ML, Prado AH, Gremiao MPD, Chorilli M. Nanotechnology Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review. Bio Med Research International. 2015; 1:1-22.
Tripathi KD. Essentials of Medical Pharmacology. Published by Jaypee Brothers Medical Publishers (P) Ltd, New Delhi. India, 1985.
Jindal S, Awasthi R, Singhare D, Kulkarni GT. Topical delivery of Tacrolimus using liposome containing gel: An emerging and synergistic approach in management of psoriasis. Med Hypotheses. 2020; 142:109838.
Rata DM, Cadinoiu AN, Atanase LI, Popa M, Mihai CT, Solcan C, Ochiuz L, Vochita G. Topical formulations containing aptamer-functionalized nanocapsules loaded with 5-fluorouracil - An innovative concept for the skin cancer therapy. Materials Sci and Engg. 2021; 119:1-12.
Sapino S, Oliaro-Bosso S, Zonari D, Zattoni A, Ugazio E. Mesoporous silica nanoparticles as a promising skin delivery system for methotrexate. Int J of Pharm. 2017; 1(2):239-248.
Krishnan V, Mitragotri S. Nanoparticles for topical drug delivery: Potential for skin cancer treatment. Adv Drug Delivery Reviews. 2020; 153:87-108.
Haque T, Rahman KM, Thurston DE, Hadgraft J, Lane ME. Topical therapies for skin cancer and actinic keratosis. European J of Pharm Sci. 2015; 77:279-289.
Mishra DK, Shandilya R, Mishra PK. Lipid based nanocarriers: a translational perspective. Nanomedicine: Nanotechnology, Biology and Medicine. 2018; 7:2023-2050.
Arien A, Dupuy B. Encapsulation of calcitonin in liposomes depends on the vesicle preparation method. J Microencapsulation. 1997; 14:753-760.
Schwarz C, Mehnert W, Lucks JS, Muller RH. Solid lipid nanoparticles (SLNs) for controlled drug delivery: I. Production, characterization and sterilization. J Control Rel. 1994; 30:83-96.
Vyas SP, Subhedar R, Jain S. Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J Pharm Pharmacol. 2006; 58:321-326.
Paliwal R, Paliwal SR, Mishra N, Mehta A, Vyas SP. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. Int J Pharma. 2009; 1(2):181-188.
Lowell GH, Kaminski RW, VanCott TC, Slike B, Kersey K, Zawoznik E, Loomis PL, Smith G, Redfield RR, Amselem S, Birx DL. Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG. J Infectious Dis. 1997; 2:292-301.
VanCott TC, Kaminski RW, Mascola JR, Kalyanaraman VS, Wassef NM, Alving CR. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol. 1998; 160:2000-2012.
Gupta S, Vyas SP. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. J Drug Target. 2007; 15:206-217.
Goldsmith DR, Perry CM. Amphotericin B lipid complex: In visceral leishmaniasis. Drugs. 2004; 64:1905-1911.
Jos S, Krishnakumar K, Dineshkumar B. Emulsomes drug delivery: A review. Int J Res Pharmac Pharm Sci. 2019; 4:13-17.
Amselem AS, Yogev A, Zawoznik E, Friedman D, Emulsomes: A novel drug delivery technology. In Proceedings of the International Symposium on the Control and Release of Bioactive Materials, 1994, pp. 1369.
Fry DW, White JC, Goldman ID. Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem. 1978; 90:809-815.
New RRC. Liposomes: a practical approach. IRL at Oxford University Press, Oxford, 1990.
Peira E, Carlotti E, Trotta C. Positively charged microemulsions for topical application. Int J Pharm. 2008; 346:119-123
Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm. 2006; 322:60-66.
Published
Abstract Display: 361 
PDF Downloads: 373 
